This report aims to provide a comprehensive presentation of the global market for Immune Thrombocytopenic Purpura Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Thrombocytopenic Purpura Therapeutics. This report contains market size and forecasts of Immune Thrombocytopenic Purpura Therapeutics in global, including the following market information:
Global Immune Thrombocytopenic Purpura Therapeutics Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Immune Thrombocytopenic Purpura Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Eltrombopag Olamine Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Immune Thrombocytopenic Purpura Therapeutics include Amgen Inc., Baxalta Incorporated, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai, Hansa Medical AB, Immunomedics, Inc., Intas Pharmaceuticals Ltd. and Jiangsu Hengrui Medicine Co., Ltd., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Immune Thrombocytopenic Purpura Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Immune Thrombocytopenic Purpura Therapeutics Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Immune Thrombocytopenic Purpura Therapeutics Market Segment Percentages, by Type, 2022 (%)
Eltrombopag Olamine
Fostamatinib Disodium
GL-2045
Avatrombopag
BI-655064
Others
Global Immune Thrombocytopenic Purpura Therapeutics Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Immune Thrombocytopenic Purpura Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Immune Thrombocytopenic Purpura Therapeutics Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Immune Thrombocytopenic Purpura Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Immune Thrombocytopenic Purpura Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Immune Thrombocytopenic Purpura Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen Inc.
Baxalta Incorporated
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eisai
Hansa Medical AB
Immunomedics, Inc.
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Immune Thrombocytopenic Purpura Therapeutics, market overview.
Chapter 2: Global Immune Thrombocytopenic Purpura Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Immune Thrombocytopenic Purpura Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Immune Thrombocytopenic Purpura Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Immune Thrombocytopenic Purpura Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Immune Thrombocytopenic Purpura Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Immune Thrombocytopenic Purpura Therapeutics Overall Market Size
2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size: 2022 VS 2030
2.2 Global Immune Thrombocytopenic Purpura Therapeutics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Immune Thrombocytopenic Purpura Therapeutics Players in Global Market
3.2 Top Global Immune Thrombocytopenic Purpura Therapeutics Companies Ranked by Revenue
3.3 Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Immune Thrombocytopenic Purpura Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Immune Thrombocytopenic Purpura Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Immune Thrombocytopenic Purpura Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Immune Thrombocytopenic Purpura Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Immune Thrombocytopenic Purpura Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Immune Thrombocytopenic Purpura Therapeutics Market Size Markets, 2022 & 2030
4.1.2 Eltrombopag Olamine
4.1.3 Fostamatinib Disodium
4.1.4 GL-2045
4.1.5 Avatrombopag
4.1.6 BI-655064
4.1.7 Others
4.2 By Type - Global Immune Thrombocytopenic Purpura Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Immune Thrombocytopenic Purpura Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Immune Thrombocytopenic Purpura Therapeutics Revenue, 2024-2030
4.2.3 By Type - Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Immune Thrombocytopenic Purpura Therapeutics Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Immune Thrombocytopenic Purpura Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Immune Thrombocytopenic Purpura Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Immune Thrombocytopenic Purpura Therapeutics Revenue, 2024-2030
5.2.3 By Application - Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Immune Thrombocytopenic Purpura Therapeutics Market Size, 2022 & 2030
6.2 By Region - Global Immune Thrombocytopenic Purpura Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Immune Thrombocytopenic Purpura Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Immune Thrombocytopenic Purpura Therapeutics Revenue, 2024-2030
6.2.3 By Region - Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Immune Thrombocytopenic Purpura Therapeutics Revenue, 2018-2030
6.3.2 US Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.3.3 Canada Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.3.4 Mexico Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Immune Thrombocytopenic Purpura Therapeutics Revenue, 2018-2030
6.4.2 Germany Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.4.3 France Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.4.4 U.K. Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.4.5 Italy Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.4.6 Russia Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.4.7 Nordic Countries Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.4.8 Benelux Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Immune Thrombocytopenic Purpura Therapeutics Revenue, 2018-2030
6.5.2 China Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.5.3 Japan Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.5.4 South Korea Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.5.5 Southeast Asia Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.5.6 India Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Immune Thrombocytopenic Purpura Therapeutics Revenue, 2018-2030
6.6.2 Brazil Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.6.3 Argentina Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Revenue, 2018-2030
6.7.2 Turkey Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.7.3 Israel Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.7.4 Saudi Arabia Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
6.7.5 UAE Immune Thrombocytopenic Purpura Therapeutics Market Size, 2018-2030
7 Immune Thrombocytopenic Purpura Therapeutics Companies Profiles
7.1 Amgen Inc.
7.1.1 Amgen Inc. Company Summary
7.1.2 Amgen Inc. Business Overview
7.1.3 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.1.4 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.1.5 Amgen Inc. Key News & Latest Developments
7.2 Baxalta Incorporated
7.2.1 Baxalta Incorporated Company Summary
7.2.2 Baxalta Incorporated Business Overview
7.2.3 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.2.4 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Baxalta Incorporated Key News & Latest Developments
7.3 Boehringer Ingelheim GmbH
7.3.1 Boehringer Ingelheim GmbH Company Summary
7.3.2 Boehringer Ingelheim GmbH Business Overview
7.3.3 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.3.4 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Boehringer Ingelheim GmbH Key News & Latest Developments
7.4 Bristol-Myers Squibb Company
7.4.1 Bristol-Myers Squibb Company Company Summary
7.4.2 Bristol-Myers Squibb Company Business Overview
7.4.3 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.4.4 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.5 Eisai
7.5.1 Eisai Company Summary
7.5.2 Eisai Business Overview
7.5.3 Eisai Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.5.4 Eisai Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Eisai Key News & Latest Developments
7.6 Hansa Medical AB
7.6.1 Hansa Medical AB Company Summary
7.6.2 Hansa Medical AB Business Overview
7.6.3 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.6.4 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Hansa Medical AB Key News & Latest Developments
7.7 Immunomedics, Inc.
7.7.1 Immunomedics, Inc. Company Summary
7.7.2 Immunomedics, Inc. Business Overview
7.7.3 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.7.4 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.7.5 Immunomedics, Inc. Key News & Latest Developments
7.8 Intas Pharmaceuticals Ltd.
7.8.1 Intas Pharmaceuticals Ltd. Company Summary
7.8.2 Intas Pharmaceuticals Ltd. Business Overview
7.8.3 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.8.4 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.8.5 Intas Pharmaceuticals Ltd. Key News & Latest Developments
7.9 Jiangsu Hengrui Medicine Co., Ltd.
7.9.1 Jiangsu Hengrui Medicine Co., Ltd. Company Summary
7.9.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
7.9.3 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.9.4 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.9.5 Jiangsu Hengrui Medicine Co., Ltd. Key News & Latest Developments
7.10 Merck & Co., Inc.
7.10.1 Merck & Co., Inc. Company Summary
7.10.2 Merck & Co., Inc. Business Overview
7.10.3 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.10.4 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.10.5 Merck & Co., Inc. Key News & Latest Developments
7.11 Momenta Pharmaceuticals, Inc.
7.11.1 Momenta Pharmaceuticals, Inc. Company Summary
7.11.2 Momenta Pharmaceuticals, Inc. Business Overview
7.11.3 Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.11.4 Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.11.5 Momenta Pharmaceuticals, Inc. Key News & Latest Developments
7.12 Novartis AG
7.12.1 Novartis AG Company Summary
7.12.2 Novartis AG Business Overview
7.12.3 Novartis AG Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.12.4 Novartis AG Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.12.5 Novartis AG Key News & Latest Developments
7.13 Pfizer Inc.
7.13.1 Pfizer Inc. Company Summary
7.13.2 Pfizer Inc. Business Overview
7.13.3 Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Major Product Offerings
7.13.4 Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue in Global Market (2018-2023)
7.13.5 Pfizer Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Immune Thrombocytopenic Purpura Therapeutics Market Opportunities & Trends in Global Market
Table 2. Immune Thrombocytopenic Purpura Therapeutics Market Drivers in Global Market
Table 3. Immune Thrombocytopenic Purpura Therapeutics Market Restraints in Global Market
Table 4. Key Players of Immune Thrombocytopenic Purpura Therapeutics in Global Market
Table 5. Top Immune Thrombocytopenic Purpura Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Immune Thrombocytopenic Purpura Therapeutics Product Type
Table 9. List of Global Tier 1 Immune Thrombocytopenic Purpura Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Immune Thrombocytopenic Purpura Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Immune Thrombocytopenic Purpura Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Immune Thrombocytopenic Purpura Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Immune Thrombocytopenic Purpura Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Immune Thrombocytopenic Purpura Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2024-2030
Table 30. Amgen Inc. Company Summary
Table 31. Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 32. Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. Amgen Inc. Key News & Latest Developments
Table 34. Baxalta Incorporated Company Summary
Table 35. Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 36. Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Baxalta Incorporated Key News & Latest Developments
Table 38. Boehringer Ingelheim GmbH Company Summary
Table 39. Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 40. Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. Boehringer Ingelheim GmbH Key News & Latest Developments
Table 42. Bristol-Myers Squibb Company Company Summary
Table 43. Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 44. Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Bristol-Myers Squibb Company Key News & Latest Developments
Table 46. Eisai Company Summary
Table 47. Eisai Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 48. Eisai Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. Eisai Key News & Latest Developments
Table 50. Hansa Medical AB Company Summary
Table 51. Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 52. Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. Hansa Medical AB Key News & Latest Developments
Table 54. Immunomedics, Inc. Company Summary
Table 55. Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 56. Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 57. Immunomedics, Inc. Key News & Latest Developments
Table 58. Intas Pharmaceuticals Ltd. Company Summary
Table 59. Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 60. Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 61. Intas Pharmaceuticals Ltd. Key News & Latest Developments
Table 62. Jiangsu Hengrui Medicine Co., Ltd. Company Summary
Table 63. Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 64. Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 65. Jiangsu Hengrui Medicine Co., Ltd. Key News & Latest Developments
Table 66. Merck & Co., Inc. Company Summary
Table 67. Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 68. Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 69. Merck & Co., Inc. Key News & Latest Developments
Table 70. Momenta Pharmaceuticals, Inc. Company Summary
Table 71. Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 72. Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 73. Momenta Pharmaceuticals, Inc. Key News & Latest Developments
Table 74. Novartis AG Company Summary
Table 75. Novartis AG Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 76. Novartis AG Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 77. Novartis AG Key News & Latest Developments
Table 78. Pfizer Inc. Company Summary
Table 79. Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Product Offerings
Table 80. Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 81. Pfizer Inc. Key News & Latest Developments
List of Figures
Figure 1. Immune Thrombocytopenic Purpura Therapeutics Segment by Type in 2022
Figure 2. Immune Thrombocytopenic Purpura Therapeutics Segment by Application in 2022
Figure 3. Global Immune Thrombocytopenic Purpura Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Immune Thrombocytopenic Purpura Therapeutics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Immune Thrombocytopenic Purpura Therapeutics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Immune Thrombocytopenic Purpura Therapeutics Revenue in 2022
Figure 8. By Type - Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 16. US Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 20. Germany Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 21. France Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 28. China Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 32. India Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 34. Brazil Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share, 2018-2030
Figure 37. Turkey Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Immune Thrombocytopenic Purpura Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 41. Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Eisai Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Novartis AG Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
